Drug major Sun Pharma and International Centre for Genetic Engineering and Biotechnology (ICGEB) have collaborated for developing a dengue vaccine targeted against all the four serotypes of dengue virus that cause diseases in humans.
ICGEB, an international organisation dedicated to advanced research and training in molecular genetics and biotechnology, has developed a tailored recombinant virus-like-particle (VLP) based tetravalent dengue vaccine. ICGEB has conducted pre-clinical studies over the past seven years and developed the existing knowhow and patents for this dengue vaccine candidate. This is the second collaboration between Sun Pharma and ICGEB focusing on dengue. The first one was related to the development of a botanical drug for treatment of dengue. The current collaboration is focussed on developing a novel, safe and effective vaccine for the prevention of dengue.
“Our new collaboration with ICGEB for developing an affordable dengue vaccine is part of our broader commitment for developing new and improved vaccines and drugs against flaviviruses that are of significant health importance to India and rest of the world. Our decision to partner with ICGEB on dengue vaccine programme followed extensive due diligence and expert consultations on existing dengue vaccine programmes globally,” Kirti Ganorkar, executive VP & head, global business development, Sun Pharma, said in a statement.
“Despite recent approval of a dengue vaccine and several candidates being at advance stage of clinical trials, the development of a safe, affordable and efficacious dengue vaccine still faces major challenges,” Dr Salunke, director – International Centre for Genetic Engineering and Biotechnology (ICGEB), said. The initial support from DBT and subsequent funding from Wellcome Trust has enabled ICGEB to bring this vaccine candidate at the stage it is today.
Sun Pharma will fund and support further development of the vaccine candidate and existing ICGEB knowhow and patents. ICGEB will grant Sun Pharma exclusive rights and licenses for development and commercialisation of this vaccine globally. ICGEB will receive pre-defined royalty and milestone payments. A joint development committee, comprising members of both the organisations, will be established to provide oversight to the dengue vaccine development program.